Literature DB >> 28914681

Randomized Controlled Trial Comparing Collagen/Oxidized Regenerated Cellulose/Silver to Standard of Care in the Management of Venous Leg Ulcers.

Breda M Cullen1, Thomas E Serena, Molly C Gibson, Robert J Snyder, Jason R Hanft, Raphael A Yaakov.   

Abstract

OBJECTIVE: To assess healing outcomes in venous leg ulcers (VLUs) treated with a combination of collagen, oxidized regenerated cellulose, and silver in conjunction with standard of care (SOC; intervention group) compared with SOC alone (control group). Standard of care included ADAPTIC nonadhering dressing (Acelity, San Antonio, Texas) and compression. DESIGN AND
SETTING: Randomized controlled trial that followed patients in 3 US facilities for 12 weeks or until complete healing. PATIENTS AND INTERVENTION: Forty-nine patients with VLUs were randomized to either the intervention group (n = 22) or the control group (n = 27). MAIN OUTCOME MEASURE: Wound healing over 12 weeks. MAIN
RESULTS: Intent-to-treat analysis showed a mean percentage wound area reduction at 12 weeks of 85.6% (SD, 28.6%) for the intervention group and 72.5% (SD, 77.8%) for the control group. There was a higher healing rate in the intervention group compared with patients who received SOC only at both week 4 (23% vs 11%) and week 12 (64% vs 59%). There were no adverse events related to the study therapy.
CONCLUSIONS: Although the results were not significant, there was a trend toward faster healing in the intervention group. The results of this study indicate that collagen/oxidized regenerated cellulose/silver is a suitable and safe adjunctive intervention for use with SOC to manage VLUs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28914681     DOI: 10.1097/01.ASW.0000524452.80170.d8

Source DB:  PubMed          Journal:  Adv Skin Wound Care        ISSN: 1527-7941            Impact factor:   2.347


  6 in total

1.  Combination therapy of oxidised regenerated cellulose/collagen/silver dressings with negative pressure wound therapy for coverage of exposed critical structures in complex lower-extremity wounds.

Authors:  Mei Ling Loh; Benjamin K L Goh; Yuan Kong; George Varughese; Jia Lin Ng; Zhiwen J Lo; Chong Han Pek
Journal:  Int Wound J       Date:  2020-05-24       Impact factor: 3.315

2.  Efficacy of Oxidized Regenerated Cellulose/Collagen Dressing for Management of Skin Wounds: A Systematic Review and Meta-Analysis.

Authors:  Li Zhang; Simei Wang; Meihua Tan; Hongwei Zhou; Ying Tang; Yan Zou
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-04       Impact factor: 2.629

Review 3.  Dressings and topical agents for treating venous leg ulcers.

Authors:  Gill Norman; Maggie J Westby; Amber D Rithalia; Nikki Stubbs; Marta O Soares; Jo C Dumville
Journal:  Cochrane Database Syst Rev       Date:  2018-06-15

4.  Allogeneic ABCB5+ mesenchymal stem cells for treatment-refractory chronic venous ulcers: a phase I/IIa clinical trial.

Authors:  Andreas Kerstan; Kathrin Dieter; Elke Niebergall-Roth; Ann-Kathrin Dachtler; Korinna Kraft; Markus Stücker; Georg Daeschlein; Michael Jünger; Tobias Görge; Ulrich Meyer-Pannwitt; Cornelia Erfurt-Berge; Charlotte von Engelhardt; Andreas Klare; Christiane Pfeiffer; Jasmina Esterlechner; Hannes M Schröder; Martin Gasser; Ana M Waaga-Gasser; Matthias Goebeler; Seda Ballikaya; Samar Sadeghi; George F Murphy; Dennis P Orgill; Natasha Y Frank; Christoph Ganss; Karin Scharffetter-Kochanek; Markus H Frank; Mark A Kluth
Journal:  JID Innov       Date:  2021-10-25

Review 5.  Enhancing wound healing dressing development through interdisciplinary collaboration.

Authors:  Briauna Hawthorne; J Kai Simmons; Braden Stuart; Robert Tung; David S Zamierowski; Adam J Mellott
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2021-05-17       Impact factor: 3.368

6.  Use of oxidised regenerated cellulose/collagen dressings versus standard of care over multiple wound types: A systematic review and meta-analysis.

Authors:  Saeed A Chowdhry; Yeni Nieves-Malloure; Mark Camardo; Julie M Robertson; Joshua Keys
Journal:  Int Wound J       Date:  2021-06-11       Impact factor: 3.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.